U.S. markets close in 3 hours 5 minutes

Regen BioPharma, Inc. (RGBP)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0380-0.0046 (-10.86%)
As of 12:40PM EDT. Market open.

Regen BioPharma, Inc.

4700 Spring Street
Suite 304
La Mesa, CA 91942
United States
619 722 5505

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. David Raymond KoosChairman, CEO, Pres, Sec. & TreasurerN/AN/A1961
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. It intends to develop small molecule NR2F6 that activates to immune cell for oncology and autoimmune diseases. The company was incorporated in 2012 and is based in La Mesa, California.

Corporate Governance

Regen BioPharma, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.